ReviewPharmaceutics2021
Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Comparative evaluation of USP II, USP IV, TIM-2, and the dynamic colon model as surrogates for human colonic drug dissolution.RSC pharmaceutics · 2026Article
- Gut Microbiota Alter Colonic Expression of Genes Encoding Drug Transporters and Drug-Metabolizing Enzymes in Mice.International journal of molecular sciences · 2026Article
- Exploration of Colonic Mucus as A Dissolution Compartment for Orally Administered Drugs.The AAPS journal · 2026Article
- Advances of Cell Membrane-Coated Nanotechnology and Membrane Vesicles in Intestinal Targeted Drug Delivery Systems.Pharmaceutics · 2026Review
- Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications.International journal of molecular sciences · 2025Review
- Emerging advances in intestinal models for in vitro preclinical research.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Nanotechnology-based Approaches for Targeted Drug Delivery to the Small Intestine: Advancements and Challenges.Current pharmaceutical design · 2025Review
- Mesoporous nanomaterial-based smart nanoplatforms for precise therapies of ulcerative colitis: Strategies and challenges.Theranostics · 2025Review
- Radiofrequency electromagnetic field ınhibits HIF-1 alpha and activates eNOS signaling to prevent intestinal damage in a model of mesenteric artery ischemia in rats.International journal of medical sciences · 2025Article
- Advanced Membrane Simulations in Probiotics and Gut Microbiome Interaction Research: The Current Trends and Insights.Current pharmaceutical design · 2025Review
- Effects of proton pump inhibitors on inflammatory bowel disease: An updated review.World journal of gastroenterology · 2024Review
- Ethylenediamine Salt Enhances the Solubility and Dissolution of Flurbiprofen.ChemistryOpen · 2024Article
- Colloidal transport phenomena in dynamic, pulsating porous materials.AIChE journal. American Institute of Chemical Engineers · 2023Article
- Article
- Nano-enabled agglomerates and compact: Design aspects of challenges.Asian journal of pharmaceutical sciences · 2023Review
- In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.Pharmaceutics · 2022Review
- Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The increasing prevalence of colonic diseases calls for a better understanding of the various colonic drug absorption barriers of colon-targeted formulations, and for reliable in vitro tools that accurately predict local drug disposition. In vivo relevant incubation conditions have been shown to better capture the composition of the limited colonic fluid and have resulted in relevant degradation and dissolution kinetics of drugs and formulations. Furthermore, drug hurdles such as efflux transporters and metabolising enzymes, and the presence of mucus and microbiome are slowly integrated into drug stability- and permeation assays. Traditionally, the well characterized Caco-2 cell line and the Ussing chamber technique are used to assess the absorption characteristics of small drug molecules. Recently, various stem cell-derived intestinal systems have emerged, closely mimicking epithelial physiology. Models that can assess microbiome-mediated drug metabolism or enable coculturing of gut microbiome with epithelial cells are also increasingly explored. Here we provide a comprehensive overview of the colonic physiology in relation to drug absorption, and review colon-targeting formulation strategies and in vitro tools to characterize colonic drug disposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.